One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene (ONC) stock just hit that mark, with a jump from 69 to 84 Wednesday.
↑ X NOW PLAYING This Is How 2025 Jobs Reports Will Impact The Fed And Rate CutsIBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
History reveals that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
BeiGene stock reclaimed its 50-day moving average on Tuesday and is working on a consolidation with a 248.16 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.
The oncology biotech company showed 0% EPS growth last quarter. Sales rose 28%.
BeiGene stock earns the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。